{"success":true,"data":{"pressRelease":{"id":"157369","rtpr_id":"nBw386Rxga-20260930","ticker":"ABLD","exchange":"Euronext Paris","all_tickers":["ABLD"],"title":"ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report","author":"Business Wire","published_at":"2026-09-30T21:30:00.084Z","article_body":"ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report\n\nRegulatory News:\n\nABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the\n“Company”), a company specializing in molecular diagnostic solutions,\nhealthcare software and services supporting clinical research, announces that\nit has made its Half-Year Financial Report for the period ended 30 June 2026\navailable to the public and filed it with the French Financial Markets\nAuthority (Autorité des Marchés Financiers – AMF).\n\nThe report is available on the Company’s website at\nhttps://www.abldiagnostics.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.abldiagnostics.com&esheet=54613878&newsitemid=20260930367594&lan=en-US&anchor=https%3A%2F%2Fwww.abldiagnostics.com&index=1&md5=ea3b2e872634bf87e5728df6af9e9820)\n, under Newsroom – Legal and Financial News.\n\nThe Board of Directors, which met on 8 September 2026, approved the interim\nfinancial statements for the six-month period ended 30 June 2026. The\nstatutory auditor’s report on the half-year financial information contains\nno observations regarding the fairness and consistency of the half-year\nmanagement report with the interim financial statements and concludes that the\nlimited review did not identify any material misstatement that would call into\nquestion the regularity and fairness of the interim financial statements.\n\nNo material differences were identified between the results presented in the\npress release dated 8 September 2026 and those presented in the Half-Year\nFinancial Report.\n\nAbout ABL Texcell Diagnostics (ABLD)\n\nABL Texcell Diagnostics (ABLD) is an international company that specializes in\ninnovative molecular biology tests and global solutions for its customers:\n\n\n * Molecular polymerase chain reaction (PCR) detection – UltraGene, and\n\n * Genotyping by DNA sequencing – DeepChek(®).\n\nABL Texcell Diagnostics markets its entire product range globally through its\nown sales team and a network of exclusive distributors active on all\ncontinents. ABL Diagnostics' customers are academic clinical pathology\nlaboratories, private reference laboratories and researchers willing to\nimplement innovative and robust microbiological content in constant expansion.\n\nFollowing the acquisition of TEXCELL’s operations, ABL Texcell Diagnostics\nis expanding its activities in the life sciences sector by integrating\nexpertise and services dedicated to virology, biosafety testing and\nbiopharmaceutical development support.\n\nABL Texcell Diagnostics has been marketing the products and services of its\nsister company CDL Pharma since the second half of 2025 through an intra-group\nstrategy agreement.\n\nAn expanding portfolio of microbiology products:\n\n\n * HIV – Drug resistance testing, including a whole genome kit.\n\n * SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.\n\n * Microbiome and taxonomy – 16s/18s RNA-based analyses.\n\n * Other viral and bacterial targets – Comprehensive molecular assays.\n\nIntegrated Solutions\n\n\n * Real-time syndromic PCR tests\n\n * Nadis(®) – Patient Medical Record used in more than 200 hospitals in France\nfor the management of HIV and hepatitis.\n\nABL Texcell Diagnostics, headquartered in Woippy, is a public limited company\nlisted on compartment B of the regulated market of Euronext in Paris\n(Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products\ngenerate recurring revenues and cover one of the largest portfolios of\napplications in microbiology.\n\nPublic limited company with a capital of €1,611,465.60\n\nRegistered office: 72C route de Thionville - 57140 WOIPPY\n\n552 064 933 R.C.S. METZ\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930367594/en/\n(https://www.businesswire.com/news/home/20260930367594/en/)\n\nABL Texcell Diagnostics SA \n\nSociété anonyme au capital de 1 611 465,60 euros\n\nHeadquarters : 72C route de Thionville - 57140 WOIPPY\n\n552 064 933 R.C.S. METZ\n\nTel : +33 (0)7 83 64 68 50\n\nEmail : info@abldiagnostics.com \n(mailto:info@abldiagnostics.com) \nhttps://www.abldiagnostics.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.abldiagnostics.com%2F&esheet=54613878&newsitemid=20260930367594&lan=en-US&anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&index=2&md5=30790b5042f9299a57cb22a6e42e9177)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw386Rxga-20260930","title":"ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report","author":"Business Wire","ticker":"ABLD","created":"2026-09-30T21:30:00.084Z","tickers":["ABLD"],"exchange":"Euronext Paris","article_body":"ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report\n\nRegulatory News:\n\nABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the\n“Company”), a company specializing in molecular diagnostic solutions,\nhealthcare software and services supporting clinical research, announces that\nit has made its Half-Year Financial Report for the period ended 30 June 2026\navailable to the public and filed it with the French Financial Markets\nAuthority (Autorité des Marchés Financiers – AMF).\n\nThe report is available on the Company’s website at\nhttps://www.abldiagnostics.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.abldiagnostics.com&esheet=54613878&newsitemid=20260930367594&lan=en-US&anchor=https%3A%2F%2Fwww.abldiagnostics.com&index=1&md5=ea3b2e872634bf87e5728df6af9e9820)\n, under Newsroom – Legal and Financial News.\n\nThe Board of Directors, which met on 8 September 2026, approved the interim\nfinancial statements for the six-month period ended 30 June 2026. The\nstatutory auditor’s report on the half-year financial information contains\nno observations regarding the fairness and consistency of the half-year\nmanagement report with the interim financial statements and concludes that the\nlimited review did not identify any material misstatement that would call into\nquestion the regularity and fairness of the interim financial statements.\n\nNo material differences were identified between the results presented in the\npress release dated 8 September 2026 and those presented in the Half-Year\nFinancial Report.\n\nAbout ABL Texcell Diagnostics (ABLD)\n\nABL Texcell Diagnostics (ABLD) is an international company that specializes in\ninnovative molecular biology tests and global solutions for its customers:\n\n\n * Molecular polymerase chain reaction (PCR) detection – UltraGene, and\n\n * Genotyping by DNA sequencing – DeepChek(®).\n\nABL Texcell Diagnostics markets its entire product range globally through its\nown sales team and a network of exclusive distributors active on all\ncontinents. ABL Diagnostics' customers are academic clinical pathology\nlaboratories, private reference laboratories and researchers willing to\nimplement innovative and robust microbiological content in constant expansion.\n\nFollowing the acquisition of TEXCELL’s operations, ABL Texcell Diagnostics\nis expanding its activities in the life sciences sector by integrating\nexpertise and services dedicated to virology, biosafety testing and\nbiopharmaceutical development support.\n\nABL Texcell Diagnostics has been marketing the products and services of its\nsister company CDL Pharma since the second half of 2025 through an intra-group\nstrategy agreement.\n\nAn expanding portfolio of microbiology products:\n\n\n * HIV – Drug resistance testing, including a whole genome kit.\n\n * SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.\n\n * Microbiome and taxonomy – 16s/18s RNA-based analyses.\n\n * Other viral and bacterial targets – Comprehensive molecular assays.\n\nIntegrated Solutions\n\n\n * Real-time syndromic PCR tests\n\n * Nadis(®) – Patient Medical Record used in more than 200 hospitals in France\nfor the management of HIV and hepatitis.\n\nABL Texcell Diagnostics, headquartered in Woippy, is a public limited company\nlisted on compartment B of the regulated market of Euronext in Paris\n(Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products\ngenerate recurring revenues and cover one of the largest portfolios of\napplications in microbiology.\n\nPublic limited company with a capital of €1,611,465.60\n\nRegistered office: 72C route de Thionville - 57140 WOIPPY\n\n552 064 933 R.C.S. METZ\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930367594/en/\n(https://www.businesswire.com/news/home/20260930367594/en/)\n\nABL Texcell Diagnostics SA \n\nSociété anonyme au capital de 1 611 465,60 euros\n\nHeadquarters : 72C route de Thionville - 57140 WOIPPY\n\n552 064 933 R.C.S. METZ\n\nTel : +33 (0)7 83 64 68 50\n\nEmail : info@abldiagnostics.com \n(mailto:info@abldiagnostics.com) \nhttps://www.abldiagnostics.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.abldiagnostics.com%2F&esheet=54613878&newsitemid=20260930367594&lan=en-US&anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&index=2&md5=30790b5042f9299a57cb22a6e42e9177)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-30T21:30:00.1296515Z","server_sent_at_ms":1790803800129},"received_at":"2026-09-30T21:30:00.181Z","source_url":"https://www.businesswire.com/news/home/20260930367594/en/"},"analysis":{"id":"146037","press_release_id":"157369","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"ABL Texcell Diagnostics filed its Half-Year Financial Report for the period ended 30 June 2026 with the French AMF and made it publicly available.\n\nThe auditor's limited review identified no material misstatement, and no differences were found versus the results already released on 8 September 2026.\n\nThis is a routine filing-availability notice with no new financial data; it carries minimal information content for investors.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine half-year report filing with clean audit review -- no new information."},"keyFigures":{"customDimensions":{"capital":"€1,611,465.60","period_end":"30 June 2026","board_approval_date":"8 September 2026"}},"namedEntities":{"people":[],"products":["UltraGene","DeepChek","Nadis"],"companies":[{"name":"ABL Texcell Diagnostics SA","ticker":"ABLD","relationship":"filer"},{"name":"Autorité des Marchés Financiers (AMF)","relationship":"regulator"},{"name":"CDL Pharma","relationship":"sister company"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine regulatory notice that the half-year financial report has been filed with the AMF. Auditor's limited review found no material misstatement and no differences vs. the previously released results; no new financial figures disclosed."},"tickerRelevance":{"others":[],"primary":"ABLD"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-regulatory-filing","issuerAuthored":true,"newInformation":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ABL Texcell Diagnostics filed its Half-Year Financial Report for the period ended 30 June 2026 with the French AMF and made it publicly available.\n\nThe auditor's limited review identified no material misstatement, and no differences were found versus the results already released on 8 September 2026.\n\nThis is a routine filing-availability notice with no new financial data; it carries minimal information content for investors.","key_figures":{"customDimensions":{"capital":"€1,611,465.60","period_end":"30 June 2026","board_approval_date":"8 September 2026"}},"named_entities":{"people":[],"products":["UltraGene","DeepChek","Nadis"],"companies":[{"name":"ABL Texcell Diagnostics SA","ticker":"ABLD","relationship":"filer"},{"name":"Autorité des Marchés Financiers (AMF)","relationship":"regulator"},{"name":"CDL Pharma","relationship":"sister company"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T21:30:03.980Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-regulatory-filing","issuerAuthored":true,"newInformation":false}},"durationMs":3768,"modelName":"glm-5.3-flashx"}}